Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DN28KM
|
|||
Drug Name |
GEN1042
|
|||
Drug Type |
Antibody
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
Company |
GenMab
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | CD40L receptor (CD40) | Target Info | Agonist | [2] |
Co-stimulatory molecule 4-1BB (CD137) | Target Info | Agonist | [2] | |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
NF-kappa B signaling pathway | ||||
Cell adhesion molecules (CAMs) | ||||
Toll-like receptor signaling pathway | ||||
Intestinal immune network for IgA production | ||||
Malaria | ||||
Toxoplasmosis | ||||
HTLV-I infection | ||||
Epstein-Barr virus infection | ||||
Transcriptional misregulation in cancer | ||||
Asthma | ||||
Autoimmune thyroid disease | ||||
Systemic lupus erythematosus | ||||
Allograft rejection | ||||
Primary immunodeficiency | ||||
Viral myocarditis | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Pathway Interaction Database | CD40/CD40L signaling | |||
Downstream signaling in naï | ||||
WikiPathways | Toll-like receptor signaling pathway | |||
Inflammatory Response Pathway | ||||
NLR Proteins | ||||
Vitamin D Receptor Pathway | ||||
Human Complement System | ||||
Allograft Rejection | ||||
Regulation of toll-like receptor signaling pathway | ||||
TCR Signaling Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04083599) GEN1042 Safety Trial in Subjects With Malignant Solid Tumors. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Genmab. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.